The WuXi AppTec-backed infectious disease therapeutics developer has closed a series C round featuring various investment managers and Singapore's sovereign wealth fund.
Brii Biosciences, a China-based infectious disease therapeutics developer backed by pharmaceutical firm WuXi AppTec, secured $155m on Tuesday for the close of a series C round that was led by investment manager Invesco’s Developing Markets Fund.
Singaporean sovereign wealth fund GIC also took part in the round alongside Lake Bleu Capital, an unnamed global investment manager, an undisclosed Asia-based investment manager and three unspecified existing backers.
Founded in 2018, Brii Biosciences is developing treatments for health conditions that cause significant…